Covid: Kevzara (sarilumab) underperforming as a therapy, according to an AP-HP study

Published by Laurent P. · Updated on 24 November 2021 at 11h15 · Published on 24 November 2021 at 10h57
According to an AP-HP study issued this November 23, 2021, Kevzara (sarilumab) - a potential cure to Covid - does not seem to have delivered conclusive results as for its effectiveness to avoid deaths after hospitalization. The study confirms results of the clinical trial led by Sanofi who announced in September 2020 they were ending their clinical trial after results of this study were inconclusive.

Kevzara (sarilumab), an underperforming cure against serious coronavirus cases… This is the conclusion made by AP-HP in a study issued this Tuesday November 23, 2021, saying the cure - that was under rolling review - does not enable to prevent deaths after hospitalization when given a few days before. The study does not "find any short-term benefit of sarilumab in mild to severe Covid-19 cases".

The study included about 150 patients hopistalized and confirms results from a previous clinical trial led a year ago by Sanofi. Sanofi laboratories announced in a press release, on Tuesday September 1, 2020 that they were ending the clinical trial on this medicine. The study, on phase 3, “has not reached its main nor its secondary assessment criteria comparatively with the placebo, and in both cases, in addition to usual hospital care” the pharmaceutical group said.

A treatment co-developed in 2017 by Sanofi and American laboratory Regeneron, first to fight against rheumatoid polyarthritis. The French laboratory conjectured that it could also have an effect on serious Covid-19 cases, and reduce lethality. The clinical trial was still on going a few days ago and including 420 patients from Argentina, Brazil, Chile, Canada, Israel, Italy, Germany, Japan, and even France and Russia.

Even though Kevzara (sarilumab) “did not deliver results we were hoping for, we are proud of the work accomplished by the team that has been entrusted with teaching us more on the potential use of Kevzara in the treatment of Covid-19Sanofi said in the release, via John Reed, the company’s international head of research and development.

A pharmaceutical group also not planning “to continue other clinical studies on Kevzara as to cure Covid-19” the release reads. 

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search